BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23833305)

  • 1. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
    Maier J; Lange T; Kerle I; Specht K; Bruegel M; Wickenhauser C; Jost P; Niederwieser D; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Sep; 19(17):4854-67. PubMed ID: 23833305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
    Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
    Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
    Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
    Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
    Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
    Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
    Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy.
    Saito K; Sakurai S; Sano T; Sakamoto K; Asao T; Hosoya Y; Nakajima T; Kuwano H
    Cancer Sci; 2008 Feb; 99(2):253-9. PubMed ID: 18271923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of gastrointestinal stromal tumors (GISTs): procedural approach for diagnostic purposes.
    Palmirotta R; De Marchis ML; Ludovici G; Leone B; Covello R; Conti S; Costarelli L; Della-Morte D; Ferroni P; Roselli M; Guadagni F
    Cancer Genomics Proteomics; 2013; 10(3):115-23. PubMed ID: 23741027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
    Braggio E; Braggio Dde A; Small IA; Lopes LF; Valadão M; Gouveia ME; Moreira Ados S; Linhares E; Romano S; Bacchi CE; Renault IZ; Guimarães DP; Ferreira CG
    Anticancer Res; 2010 Jun; 30(6):2407-14. PubMed ID: 20651400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
    Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
    Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
    Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.
    Rizzo FM; Palmirotta R; Marzullo A; Resta N; Cives M; Tucci M; Silvestris F
    BMC Cancer; 2016 Feb; 16():87. PubMed ID: 26867653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.